Treating ADHD Alongside Stimulant-Use Disorder

The Psychiatric Record | Clinical Practice

When ADHD and stimulant-use disorder coexist, the prescribing decision contains two questions: what might improve attention and function, and what might change substance use? A favorable result on one outcome does not settle the other. A new review makes that distinction worth keeping in view.

An August 31 network meta-analysis in the Journal of Clinical Psychiatry included six studies of adults with both conditions, examining methylphenidate, mixed amphetamine salts, and bupropion. Its abstract reports that mixed amphetamine salts 80 mg ranked highest for continuous abstinence and negative urine tests; methylphenidate 180 mg ranked highest for improvement in ADHD symptoms. The authors described safety profiles as comparable with placebo and supported considering optimized stimulant dosing, while calling for further trials. [1]

These are studied doses, not starting doses or a prescribing schedule. This discussion uses the review's abstract and reference list; its full methods and trial-level analyses were not reviewed.

The rankings alone cannot establish how well the results travel to a different clinical setting. Nor does a summary of comparable safety establish that uncommon harms, longer treatment, or patients excluded from trials pose the same risks.

The review cites a 2015 randomized trial by Levin and colleagues and a later secondary analysis of it. Its abstract does not describe their contributions to the network. [1] The trial shows what a drug-and-dose label leaves out.

The investigators randomized 126 adults with ADHD and cocaine use disorder to extended-release mixed amphetamine salts targeting 60 or 80 mg daily, or placebo, for 13 weeks. Scheduled care included three clinic visits per week with urine collection, weekly cognitive behavioral therapy, and safety assessments. Doses could be reduced or suspended for tolerability; cocaine outcomes were classified weekly. [2]

The numerical pattern differed by target. Cocaine-negative weeks favored 80 mg numerically. ADHD response, defined as at least 30% symptom reduction, occurred in 75.0% at 60 mg, 58.1% at 80 mg, and 39.5% on placebo. Only 60 mg reached significance against placebo on that response measure. Direct dose comparisons were not significant for either ADHD response (P = .09) or cocaine-negative weeks (P = .11); both doses improved mean ADHD scores versus placebo. [2]

This is a reason to track each target separately, not proof of a different optimal dose for each condition. The follow-up arrangements also belong in the interpretation of treatment benefit.

ASAM/AAAP recommendation 26 supports treating co-occurring ADHD: consider stimulants when benefits exceed risks, nonstimulants otherwise, and behavioral treatment. All these items carry low-certainty evidence but strong recommendations. [3]

Recommendation 27 rests on clinical consensus: considering extended-release preparations is strong; tailoring monitoring to medication and patient risk is conditional.

The guideline's above-label dosing items concern treating stimulant-use disorder itself: long-acting amphetamines for cocaine-use reduction (19b, low certainty, conditional) and long-acting methylphenidate for amphetamine-type stimulant-use reduction (20c, low certainty, weak), at or above FDA ADHD maxima. This recommendation set applies only to addiction-board-certified physicians or physicians with comparable training, competencies, and close-monitoring capacity (15, clinical consensus, strong). Within that scope, clinicians can give these agents additional consideration when ADHD co-occurs (19a, 20b; low certainty, conditional).

The target also changes the strength of the monitoring recommendation: risk-matched monitoring is strong when prescribing for stimulant-use disorder (16), conditional for co-occurring ADHD (27b). Both rest on clinical consensus. Both name the same examples (pill counts, drug testing, closer clinical contact, and more frequent prescription-database checks), and neither makes them a mandatory bundle.

That scope matters. Treating ADHD in someone who also uses stimulants and prescribing a stimulant specifically to treat stimulant-use disorder are different clinical intentions. The plan should say which is intended, or whether both are being targeted, rather than letting one purpose drift into the other.

For ADHD, identify the symptoms and functional changes that would count as benefit. For substance use, identify the intended outcome and the observations that will help assess it. As our earlier article, Reduced Stimulant Use Is Not Treatment Failure, discussed, the choice of outcome matters when interpreting progress.

Then make the review process explicit. Who will assess the information? What would prompt reconsideration? How will the patient report ongoing use, difficulty taking the medication, or unwanted effects? A monitoring list becomes useful when those observations can change the next decision.

The new review gives clinicians a reason to take potential benefit seriously. Translating that benefit into care still requires a stated treatment target, an individualized risk assessment, and follow-up that the patient and treating team can actually carry out.

1. Oliva HNP, Pulido-Saavedra A, Paredes Naveda AM, et al. Pharmacotherapies for Co-Occurring Stimulant Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Network Meta-Analysis. J Clin Psychiatry. 2026;87(4):26r16478. Published August 31, 2026. doi:10.4088/JCP.26r16478. Abstract and reference list.

2. Levin FR, Mariani JJ, Specker S, et al. Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2015;72(6):593-602. doi:10.1001/jamapsychiatry.2015.41. Full-text methods and results reviewed.

3. The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder. J Addict Med. 2024;18(1S Suppl 1):1-56. Recommendations 15, 16, 19, 20, 26, and 27.

Educational Disclaimer: The Psychiatric Record provides general educational information for psychiatric and mental-health professionals. Content does not constitute medical, legal, regulatory, compliance, billing, or other professional advice; does not establish a standard of care; and is not a substitute for independent professional judgment. Appropriate assessment and treatment depend on the individual, setting, and current authoritative guidance. This article is not a stimulant prescribing, dosing, or monitoring protocol.